Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001853:Bone Marrow / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D011034:Podophyllotoxin